Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial

Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).

(2021) Alison Jane Birtle et al.   JOURNAL OF CLINICAL ONCOLOGY

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

(2021) Thomas Powles et al.   NATURE MEDICINE

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

(2021) Dean F. Bajorin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

(2021) Yung Lyou et al.   Clinical Genitourinary Cancer

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

(2021) Milind Javle et al.   Lancet Gastroenterology & Hepatology

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

(2021) T. Powles et al.   ANNALS OF ONCOLOGY

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

(2020) Alison Birtle et al.   LANCET

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results

(2020) Sumanta K. Pal et al.   CANCER

Molecular targeted therapies: Ready for “prime time” in biliary tract cancer

(2020) Angela Lamarca et al.   JOURNAL OF HEPATOLOGY

Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy

(2020) Jeffrey J. Leow et al.   EUROPEAN UROLOGY

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

(2020) Yung Lyou et al.   EUROPEAN UROLOGY

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

(2020) M. Teresa Magone et al.   OPHTHALMOLOGY

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

(2019) Nazli Dizman et al.   JOURNAL OF CLINICAL ONCOLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

(2018) A. Gordon Robertson et al.   CELL

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

(2018) François Audenet et al.   CLINICAL CANCER RESEARCH

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets

(2017) Eugene J. Pietzak et al.   EUROPEAN UROLOGY

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma

(2017) Tyler J. Moss et al.   EUROPEAN UROLOGY

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

(2017) Sam S. Chang et al.   JOURNAL OF UROLOGY

New option for cisplatin-ineligible urothelial cancer

(2017) Robert Dreicer   LANCET ONCOLOGY

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma

(2016) Aditya Bagrodia et al.   JOURNAL OF UROLOGY

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

(2015) Jeffrey S. Ross et al.   CANCER

Genomic Characterization of Upper Tract Urothelial Carcinoma

(2015) John P. Sfakianos et al.   EUROPEAN UROLOGY

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update

(2015) Morgan Rouprêt et al.   EUROPEAN UROLOGY

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up

(2014) J. Bellmunt et al.   ANNALS OF ONCOLOGY

FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer

(2014) R. Wang et al.   CLINICAL CANCER RESEARCH

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

(2012) D. Singh et al.   SCIENCE

Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease

(2011) N. Itoh et al.   JOURNAL OF BIOCHEMISTRY

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

(2011) Matthew D Galsky et al.   LANCET ONCOLOGY